Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors

Magali Waelbroeck a, Jean Camus a, Michèle Tastenoy a, Ernst Mutschler b, Carsten Strohmann c, Reinhold Tacke c, Lise Schjelderup d, Arne Aasen d, Günter Lambrecht b and Jean Christophe a

a Department of Biochemistry and Nutrition, Medical School, Free University of Brussels, B-1070 Brussels, Belgium, b Department of Pharmacology, University of Frankfurt, D-6000 Frankfurt am Main, Germany, c Institute of Inorganic Chemistry, University of Karlsruhe, D-7500 Karlsruhe, Germany, and d Department of Pharmacy, University of Oslo, N-0316 Oslo, Norway

Received 7 April 1992, accepted 28 April 1992

We investigated the binding properties of the (R)- and (S)-enantiomers of the muscarinic antagonists trihexyphenidyl, procyclidine, hexahydro-difenidol, p-fluoro-hexahydro-difenidol, hexbutinol, p-fluoro-hexbutinol, and their corresponding methiodides at muscarinic M 1, M 2, M 3 and M 4 receptor subtypes. In addition, binding properties of the (R)- and (S)-enantiomers of oxyphencyclimine were studied. The (R)-enantiomers (eutomers) of all the compounds had a greater affinity than the (S)-enantiomers for the four muscarinic receptor subtypes. The binding patterns of the (R)- and (S)-enantiomers were generally different. We did not observe any general correlation between the potency of the high-affinity enantiomer and the affinity ratio (eudismic ratio) of the two enantiomers. The results are discussed in terms of a ‘four subsites’ binding model.

Muscarnic receptors; Hexahydro-difenidol; Hexbutinol; Oxyphencyclimine; Eudismic analysis; Pleiffer’s rule; Stereoselectivity; Receptor interaction

1. Introduction

At least four muscarinic receptors can now be discriminated in radioligand experiments (Lazareno and Roberts, 1989; Michel et al., 1989; Lazareno et al., 1990; Waelbroeck et al., 1990a) and in pharmacological studies (Dörje et al., 1990), using a battery of selective antagonists. The M 1 receptors have the highest affinity for pirenzipine (Hammer et al., 1980), the M 2 receptors, the highest affinity for AF-DX 116 (Giachetti et al., 1986) and the M 3 and M 4 receptors have higher affinities than M 2 receptors for 4-diphenylacetoxy-N-methyl piperidine methiodide (4-DAMP) (Barlow et al., 1976) and for hexahydro-sila-difenidol (Mutschler and Lambrecht, 1984; Lambrecht et al., 1989). The cardioselective drugs himbacine (Gilani and Cobbing, 1986) and methotramine (Melchiorre et al., 1987) can be used to discriminate them from each other, because they have a higher affinity for M 4 than M 3 receptors.

The tissue distribution and antagonist binding properties of the M 1, M 2, M 3 and M 4 receptors are comparable to the tissue distribution of the m1, m2, m3 and m4 messenger RNAs and to the binding properties of the corresponding cloned receptors expressed in different cell lines (Bonner, 1989; Levine and Birdsal, 1989; Dörje et al., 1991).

In the last few years, data have been accumulated suggesting that the muscarinic receptor subtypes can also be differentiated on the basis of their stereoselectivity (see below). A special vocabulary was introduced to describe these data (Lehmann, 1986). The enantiomer with the higher affinity for the receptors is called the ‘eutomer’, the less affinity, the ‘distomer’. Their affinity ratio (‘eudismic ratio’) is a measure of the receptor’s stereoselectivity. Its logarithm, the ‘eudismic index’, is proportional to the difference between the binding free energies of the eutomer and distomer. The eudismic index of chiral muscarinic antagonists, such as procyclidine (Lambrecht and Mutschler, 1986; Tacke et al., 1986; Waelbroeck et al., 1990b), trihexyphenidyl and its methiodide (Lambrecht et al., 1988), biperiden (Elte and Figala, 1988), hexahydro-difenidol and hexbutinol (Feisel et al., 1990) as
weil as telenzepine (Eveleigh et al., 1989) has been used as an additional criterion for receptor classification. In the case of muscarinic antagonists carrying a 1,3-oxathiolane nucleus, there was also a clear-cut difference between the eudismic affinity quotient (which measures the variation of the eudismic index with eutomer affinity) when comparing the muscarinic receptors in the heart, bladder or ileum (Guaitieri et al., 1990), supporting the hypothesis that these receptors are different.

We compared in this work the affinity and stereoselectivity of the enantiomers of several tertiary and quaternary chiral antagonists (see fig. 1), all possessing a hydroxy, phenyl, and cyclohexyl group bound to the centre of chirality, but differing in the structure of the basic amino ( ammonium) group and the structure of the chain connecting the carbino1 carbon atom and the cationic head (fig. 1). In addition, four analogues with a para-fluoro-phenyl rather than phenyl group (fig. 1) were investigated. Affinity data were obtained in competition experiments using $[^3H]$N-methylscopolamine as radioligand. The receptors studied were the NB-OK 1 neuroblastoma (M₁), rat cardiac (M₂), and pancreas (M₃) receptors, and the rat striatum receptors with M₄ binding properties. Our goals were 2-fold: (a) test the hypothesis that the receptor's stereoselectivity or eudismic affinity quotient can be used in combination with affinity values for receptor classification; (b) obtain a better understanding of the basis of enantiomer discrimination by muscarinic receptors (binding model).

The functional properties of the enantiomers of trihexyphenidyl (compound 1 in fig. 1) and its methiodide (2) (Lambrecht et al., 1985), procyclidine (3) and tricyc lamol (4) (Tacke et al., 1986), hexahydro-difenidol (5) as well as hexbutinol (9), its methiodide (10) and p-fluoro-hexbutinol (11) (Feifei et al., 1990) to muscarinic receptor subtypes have been reported elsewhere. The binding affinities of the enantiomers of compounds 3 and 5–8 at muscarinic receptor subtypes have also been described (Waelbroeck et al., 1990b, 1991a,b).

2. Materials and methods

2.1. Cell and tissue preparations

Human NB-OK 1 neuroblastoma cells (a generous gift from Dr. Yanaihara, Shizuoka, Japan) were maintained in RPMI 1640 medium, enriched with 100 U/ml

Fig. 1. Chemical structure of the compounds (1–13) investigated in this study.
penicillin, 100 μg/ml streptomycin and 10% foetal calf serum (from Gibco, Gent, Belgium). Twice a week the cells were detached by trypsin-EDTA (Gibco, Gent, Belgium) and divided 1/3. For [1H]N-methyl scopolamine ([1H]NMS) binding experiments, the cells were harvested using a 20 mM sodium phosphate buffer enriched with 1 mM EDTA and 150 mM NaCl (pH 7.4), centrifuged at 500 × g for 5 min, resuspended and homogenized in 20 mM Tris-HCl buffer enriched with 5 mM MgCl₂ (pH 7.5) in a glass-Teflon homogenizer, and then stored in liquid nitrogen until use.

For cardiac homogenates male Wistar albino rats (200–250 g) were killed by decapitation, and the heart was immediately removed and rinsed in 150 mM NaCl. The homogenization buffer contained 20 mM Tris-HCl (pH 7.5) and 250 mM sucrose. Each heart was homogenized in 2 ml of this buffer with an Ultraturrax homogenizer (maximal speed for 5 × 4°C) followed by further addition of 13 ml of buffer, and 7 up and down strokes in a glass-Teflon homogenizer (at 4°C). The homogenate was filtered on two layers of medical gauze and either used immediately or stored in liquid nitrogen until use.

For rat striatum homogenates the brain was immediately removed and dissected. The striatum was homogenized in 2 ml of 20 mM Tris-HCl buffer (pH 7.5) enriched with 250 mM sucrose, with a glass-Teflon homogenizer, and stored in liquid nitrogen until use. These homogenates were diluted 20-fold with the homogenization buffer before use for [1H]NMS binding experiments.

For rat pancreas homogenates the organ was immediately removed, minced with scissors and homogenized in a glass-Teflon homogenizer (7 up and down strokes at 4°C) in a solution containing 300 mM sucrose, 0.2 mg/ml bacitracin and 500 kallikrein inhibitor U/ml of Trasylol (Bayer, Brussels, Belgium). The resulting homogenate was immediately filtered on two layers of medical gauze and diluted 11-fold with the incubation buffer.

2.2. [3H]NMS binding experiments

[3H]NMS binding was measured at 25°C in a total volume of 1.2 ml using the following incubation buffer: 50 mM sodium phosphate (pH 7.4) enriched with 2 mM MgCl₂, 1% bovine serum albumin (except when indicated) and the indicated tracer and drug concentrations. Addition of bovine serum albumin to the incubation buffer increased [3H]NMS binding very slightly (by at most 10–15%) and improved the reproducibility of duplicates in our filtration assays. In binding experiments on pancreas homogenates, we also added Trasylol and bacitracin (see above) to further inhibit proteolytic activity. Bovine serum albumin was an essential ingredient in pancreas binding studies, since the binding capacity of pancreas homogenates disappeared within 40 min at room temperature if this protein was omitted from the buffer, but was maintained over 90% for at least 4 h in its presence.

To terminate the incubation, each sample was diluted with 2 ml of ice-cold 50 mM sodium phosphate buffer (pH 7.4) and filtered on GF/C glass-fibre filters (Whatman, Maidstone, UK) presoaked in 0.05% polyethylenimine. The filters were rinsed 3 times with the same filtration buffer, dried, and the radioactivity (bound tracer) counted by liquid scintillation. Non-specific binding was defined as [1H]NMS binding in the presence of 1 μM atropine.

For [3H]NMS binding to human NB-OK 1 cell homogenates, a 0.25 nM tracer concentration (2-fold Kᵢ for M₄ receptors) was chosen with a homogenate concentration of 160–200 μg protein per assay (about 50 pM binding sites) and an incubation period of 2 h at 25°C allowing full equilibration of tracer binding.

In binding experiments on rat cardiac homogenates, a 1 mM [3H]NMS concentration (2-fold Kᵢ for M₂ receptors) was selected with a homogenate concentration of 400–500 μg protein per assay (about 250 pM binding sites) and a 2 h incubation period at 25°C allowing full equilibration of tracer binding.

In binding experiments on rat striatum homogenates, the tracer concentration was 0.25 nM and the protein concentration 30–40 μg per assay (about 50 pM binding sites). Under equilibrium conditions (2 h incubation at 25°C) [3H]NMS labelled M₁, M₃ and M₄ sites in this brain region. To analyze tracer binding to M₄ sites only, we preincubated striatum homogenates for 2 h at 25°C to allow equilibrium binding, then induced tracer dissociation by adding 1 μM atropine. [3H]NMS dissociated from its binding sites after 35 min of isotopic dilution, the residual binding being about 30% of initial binding. Since [3H]NMS dissociation from M₄ sites is faster than that from M₃ and M₂ sites, 85% of this residual [3H]NMS binding corresponded to M₄ binding sites (Waelbroeck et al., 1990a).

It is necessary to keep tracer binding below 15% of the total tracer added to avoid distortions of the competition curves due to tracer or unlabelled drug depletion. This means that the residual tracer binding to striatum M₄ (+M₃) sites in the absence of unlabelled drug must be maintained below 5% of the total tracer added (i.e. 30% of the 15% initial binding). We therefore decided to use a comparatively high [3H]NMS concentration (0.25 nM, equivalent to 5-fold Kᵢ at M₄ sites) for these experiments.

In binding experiments on rat pancreas homogenates we used 980 μl of the homogenate per 1.2 ml sample. The [3H]NMS concentration was 0.25 nM (2-fold Kᵢ at M₃ receptors) and protein concentration 800–1000 μg per assay (about 50 pM binding sites). An
incubation period of 4 h was necessary to allow binding equilibrium.

Protein concentration was measured according to Lowry et al. (1951) using bovine serum albumin as standard.

2.3. Data analysis and statistics

The competition curves for unlabelled antagonists 1–13 (fig. 1) were analyzed using the computer program described by Richardson and Humrich (1984), and were compatible with the existence of a single receptor subtype. Kᵢ values were calculated from IC₅₀ values using the Cheng and Prusoff (1973) equation. The pKᵢ values, presented in table 1 and figs. 2 and 3 as means, were defined as −log Kᵢ. Each experiment was repeated at least 3 times. The standard deviation of each IC₅₀ value was below 30% of the average value in all cases (corresponding to pKᵢ, standard deviations of < 0.1 log unit) and was therefore not mentioned in table 1 and figs. 2 and 3.

2.4. Drugs and chemicals

[³H]N-methyl-scopolamine ([³H]NMS, 74 Ci/mmol) was obtained from Amersham International (Bucks., UK). Atropine, polyethyleneimine and bovine serum albumin (Cohn fraction V) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Tissue culture material and media were obtained from Gibco (Gent, Belgium). All other chemicals were of the highest grade available.

The (R)- and (S)-enantiomers of trihexyphenidyl ((R)-1 and (S)-1; as hydrochlorides) (Schjelderup et al., 1987) and trihexyphenidyl methiodide ((R)-2 and (S)-2) (Schjelderup et al., 1987 and unpublished results), procyclidine ((R)-3 and (S)-3) (Tacke et al., 1986), tricyclamol iodide ((R)-4 and (S)-4) (Tacke et al., 1986), hexahydro-difenidol ((R)-5 and (S)-5; as hydrochlorides) (Tacke et al., 1989), p-fluoro-hexahydro-difenidol ((R)-7 and (S)-7 as hydrochlorides) (Strohmann et al., 1991), p-fluoro-hexahydro-difenidol methiodide ((R)-8 and (S)-8) (Strohmann et al., 1991), hexbutinol ((R)-9 and (S)-9) (Tacke et al., 1989), hexbutinol methiodide ((R)-10 and (S)-10) (Feipel et al., 1990), and p-fluoro-hexbutinol ((R)-11 and (S)-11) (Strohmann et al., 1991) and oxyphencyclimine ((R)-12 and (S)-12, as hydrochlorides) (Schjelderup et al., 1988) were synthesized according to the literature. The (S)-enantiomer of p-fluoro-hexbutinol methiodide ((R)-12 and (S)-12) was also synthesized according to the literature (Strohmann et al., 1991; in this paper, the sign of the optical rotation of (S)-12 is wrong; (S)-12 is not the laevorotatory, but the dextrorotatory enantiomer).

The enantiomers of hexahydro-difenidol methiodide ((R)-6 and (S)-6) were prepared by quaternization of (R)-5 and (S)-5, respectively, with methyl iodide in acetone, following the procedure described for the synthesis of (R)-8 and (S)-8 (see Strohmann et al., 1991).

(R)-6: C₂₂H₃₅NO (457.4), yield 84%, m.p. 138–139°C (acetone/dichloromethane, colourless needles), [α]D⁰ = −14 (c = 0.5, CHCl₃), ee > 99.7%. Found: C, 57.4; H, 8.3; N, 3.0. Calculated: C, 57.77; H, 7.93; N, 3.06. Structural characterization by ¹H and ¹³C NMR spectroscopic studies (data not given).

(S)-6: C₂₂H₃₅NO (457.4), yield 88%, m.p. 138–139°C (acetone/dichloromethane, colourless needles), [α]D⁰ = 14 (c = 0.5, CHCl₃), ee > 99.7%. Found: C, 57.4; H, 8.3; N, 3.0. Calculated: C, 57.77; H, 7.93; N, 3.06. Structural characterization by ¹H and ¹³C NMR spectroscopic studies (data not given).

The (R)-enantiomer of p-fluoro-hexbutinol methiodide ((R)-12) was prepared by quaternization of (R)-11.

<table>
<thead>
<tr>
<th>Muscarinic agonist No. (name)</th>
<th>M₁ (NB-OK 1) (R)/ (S)</th>
<th>M₂ (heart) (R)/ (S)</th>
<th>M₃ (pancreas) (R)/ (S)</th>
<th>M₄ (in striatum) (R)/ (S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (trihexyphenidyl)</td>
<td>8.9/6.5</td>
<td>7.7/6.1</td>
<td>8.1/5.5</td>
<td>8.8/6.3</td>
</tr>
<tr>
<td>2 (trihexyphenidyl methiodide)</td>
<td>9.6/7.4</td>
<td>8.6/6.9</td>
<td>8.6/6.4</td>
<td>9.2/7.0</td>
</tr>
<tr>
<td>3 (procyclidine)</td>
<td>8.4/6.2 *</td>
<td>7.3/5.8 *</td>
<td>7.8/5.5</td>
<td>8.1/6.0 *</td>
</tr>
<tr>
<td>4 (tricyclamol iodide)</td>
<td>9.4/6.9</td>
<td>8.3/6.6</td>
<td>8.1/5.9</td>
<td>8.9/6.5</td>
</tr>
<tr>
<td>5 (hexahydro-difenidol) b</td>
<td>8.2/6.1</td>
<td>7.0/5.8</td>
<td>7.9/6.0</td>
<td></td>
</tr>
<tr>
<td>6 (hexahydro-difenidol methiodide) b</td>
<td>8.6/6.5</td>
<td>8.2/6.0</td>
<td>8.1/5.5</td>
<td>8.4/6.1</td>
</tr>
<tr>
<td>7 (p-fluoro-hexahydro-difenidol)</td>
<td>7.9/5.9 b</td>
<td>6.7/5.6 b</td>
<td>7.9/5.8</td>
<td>7.9/5.8 b</td>
</tr>
<tr>
<td>8 (p-fluoro-hexahydro-difenidol methiodide)</td>
<td>8.4/6.3 b</td>
<td>7.8/5.9 b</td>
<td>8.2/6.2</td>
<td>8.2/6.2 b</td>
</tr>
<tr>
<td>9 (hexbutinol)</td>
<td>8.9/7.3</td>
<td>8.9/7.0</td>
<td>-</td>
<td>9.3/8.2</td>
</tr>
<tr>
<td>10 (hexbutinol methiodide)</td>
<td>8.8/7.6</td>
<td>8.3/7.4</td>
<td>-</td>
<td>9.0/7.8</td>
</tr>
<tr>
<td>11 (p-fluoro-hexbutinol)</td>
<td>8.2/6.0</td>
<td>7.3/7.1</td>
<td>-</td>
<td>8.4/8.3</td>
</tr>
<tr>
<td>12 (p-fluoro-hexbutinol methiodide)</td>
<td>-3.3/8.0</td>
<td>7.8/7.5</td>
<td>-</td>
<td>8.4/8.8</td>
</tr>
<tr>
<td>13 (oxyphencyclimine)</td>
<td>9.0/7.5</td>
<td>8.7/7.1</td>
<td>-</td>
<td>9.2/7.5</td>
</tr>
</tbody>
</table>

* Data taken from Waclbroeck et al., 1990b; b data taken from Waclbroeck et al., 1991a.
with methyl iodide in acetone, following the procedure described for the synthesis of (S)-12 (see Strohmann et al., 1991). (R)-12: C_{22}H_{31}FNO (471.4), yield 82%, m.p. (dec.) 190°C (acetone/diethyl ether, colourless needles). \( [\alpha]_{D}^{25} = -2 \) (c = 0.5, CHCl_3), ee > 99.8%. Found: C, 56.2; H, 6.5; N, 2.9. Calculated: C, 56.06; H, 6.63; N, 2.97. Structural characterization by \(^1\)H and \(^{13}\)C NMR spectroscopic studies (data not given).

3. Results

3.1. General considerations

All the competition curves obtained in this study were compatible with the existence of a single receptor subtype in the different preparations with Hill coefficients not significantly different from unity (n_H varied between 0.95 and 1.10, with standard deviations below or equal to 0.05). This suggested that [\(^3\)H]NMS labelled single binding sites in each tissue or cell type.

Competition curves with (R)- and (S)-hexbutinol, (R)- and (S)-9 and (R)- and (S)-10-11 and -12 analogues and oxyphencyclidine ((R)- and (S)-13) were shifted to the right by 0.5-1.0 log units in all preparations in the presence of 1% bovine serum albumin (data not shown). We therefore determined the binding affinities of the enantiomers of compounds 9-13 to muscarinic receptors in homogenates from human NB-OK 1 cells, rat heart and striatum in the absence of bovine serum albumin, pK_i values are given in table 1.

The binding properties of the (R)- and (S)-enantiomers of p-fluoro-hexahydro-difenidol (7) and its methiodide (8) to rat pancreas receptors were previously estimated by comparison of competition curves in pancreas and brain cortex with 1% bovine serum albumin in the incubation buffer (see Materials and methods) and in cortex without bovine serum albumin (Wadbroeck et al., 1991a).

3.2. Receptor binding profiles of the (R)- and (S)-enantiomers

As shown in table 1, the receptor binding profiles of the (R)- and (S)-enantiomers of the chiral drugs 1-13 were generally different. (R)-Trihexyphenidyl ((R)-1), (R)-trihexyphenidyl methiodide ((R)-2), (R)-procyclidine ((R)-3) and (R)-tricyclamol iodide ((R)-4) had a clear M_1 > M_2 selectivity, high affinities for M_1 sites and intermediate or low affinities for the M_2 sites. In contrast, their (S)-enantiomers had an M_3 > M_1 selectivity, with intermediate affinities for the M_2 and M_4 sites. (R)-Hexahydro-difenidol ((R)-5) and (R)-p-fluoro-hexahydro-difenidol ((R)-7) had a preference for M_1, M_3 and M_4 over M_2 sites, while (S)-hexahydro-difenidol and (S)-p-fluoro-hexahydro-difenidol were non-selective. (R)-Hexahydro-difenidol methiodide ((R)-6) was almost non-selective, but (S)-hexahydro-difenidol methiodide M_1 > M_3 preferring. (R)-Hexbutinol ((R)-9) was M_1, M_4 > M_2 preferring, but (S)-hexbutinol ((S)-9) selective for M_4 over M_1 and M_2 sites. In contrast with these results, the (R)- and (S)-enantiomers of p-fluoro-hexbutinol (11) and p-fluoro-hexbutinol methiodide (12) had the same selectivity for M_1, M_4 > M_2 sites. The (R)- and (S)-enantiomers of p-fluoro-hexahydro-difenidol methiodide (8), hexbutinol methiodide (10) and oxyphencyclidine (13) were almost non-selective.

3.3. Stereoselectivity at muscarinic receptors

The (R)-enantiomers (eutomers) of compounds 1-13 displayed higher affinities for M_1-M_4 receptors than the (S)-isomers (diastomers), the eudismic indexes vary-

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscarinic antagonist</td>
</tr>
<tr>
<td>1 (trihexyphenidyl)</td>
</tr>
<tr>
<td>2 (trihexyphenidyl methiodide)</td>
</tr>
<tr>
<td>3 (procyclidine)</td>
</tr>
<tr>
<td>4 (tricyclamol iodide)</td>
</tr>
<tr>
<td>5 (hexahydro-difenidol)</td>
</tr>
<tr>
<td>6 (hexahydro-difenidol methiodide)</td>
</tr>
<tr>
<td>7 (p-fluoro-hexahydro-difenidol)</td>
</tr>
<tr>
<td>8 (p-fluoro-hexahydro-difenidol methiodide)</td>
</tr>
<tr>
<td>9 (hexbutinol)</td>
</tr>
<tr>
<td>10 (hexbutinol methiodide)</td>
</tr>
<tr>
<td>11 (p-fluoro-hexbutinol)</td>
</tr>
<tr>
<td>12 (p-fluoro-hexbutinol methiodide)</td>
</tr>
<tr>
<td>13 (oxyphencyclidine)</td>
</tr>
</tbody>
</table>
Fig. 2. The eudismic indexes of the phenyl compounds (1–6, 9, 10 and 13) (circles) and the p-fluorophenyl derivatives (7, 8, 11 and 12) (triangles) were plotted as a function of the enantiomer affinity. The numbers identify the compounds shown in fig. 1 and table 1, and the correlation lines are described in table 3. Top panel: M₁ receptors; bottom panel: M₂ receptors.

As shown in table 2, the enantioselectivity ratios of compounds 1–5 and 7 consistently showed the same order: M₁ = M₃ > M₂. This implies that the stereochemical demands made by the muscarinic receptor subtypes were different for the enantiomers of compounds 1–5 and 7, being least stringent at M₂ receptors. In contrast, the eudismic indexes for the two

TABLE 3

The correlation lines shown in figs. 2 and 3 can be described as 'eudismic index = a + b (pKᵢ)' with the indicated values of 'a' and 'b'. The correlation coefficient r, and the probability (P) that the slope is different from zero are also indicated.

<table>
<thead>
<tr>
<th>Receptor subtype</th>
<th>Compound No.</th>
<th>a</th>
<th>b</th>
<th>r</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>M₁</td>
<td>1 → 8</td>
<td>-0.56</td>
<td>0.19±0.09</td>
<td>0.68</td>
<td>&lt;0.10</td>
</tr>
<tr>
<td>M₁</td>
<td>2, 4, 9 → 13</td>
<td>-13.17</td>
<td>1.63±0.13</td>
<td>0.98</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>M₂</td>
<td>1 → 8</td>
<td>-1.61</td>
<td>0.42±0.12</td>
<td>0.77</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>M₂</td>
<td>2, 9 → 13</td>
<td>-8.06</td>
<td>1.11±0.26</td>
<td>0.95</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>M₃</td>
<td>1 → 8</td>
<td>0.46</td>
<td>0.23±0.32</td>
<td>0.26</td>
<td>n.s.</td>
</tr>
<tr>
<td>M₄</td>
<td>1 → 8</td>
<td>-0.34</td>
<td>0.30±0.11</td>
<td>0.72</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>M₅</td>
<td>2, 9 → 13</td>
<td>-12.14</td>
<td>1.49±0.59</td>
<td>0.82</td>
<td>&lt;0.10</td>
</tr>
</tbody>
</table>

*a* is the eudismic index expected for a compound with a pKᵢ = 0 (Ki value = 1 molar) and 'b', sometimes called 'eudismic affinity quotient', measures the slope of the line (i.e. the variation of stereoselectivity with affinity). n.s. = not significant.
methiodides 6 and 8 were very similar (1.9-2.6) at the four receptor subtypes. This was mainly based on the fact that N-methylation selectively increased the affinity of the (R)-enantiomers of the tertiary amines 5 and 7 at M₂ receptors by more than one order of magnitude.

The compounds 9-12 with a triple bond within the molecule had a lower eudismic index than the saturated drugs 1-8 (table 2) at all subtypes studied. The same held true for oxyphencyclidine at M₁ and M₄ receptors.

3.4. Correlation of the eutomer affinity and eudismic index

We plotted in figs. 2 and 3 the eudismic index (difference between the pKi values of the (R)- and (S)-enantiomers) as a function of the affinity (pKi value) of the (R)-enantiomer (eutomer). We found no significant correlation between the affinity constants of either all the eutomers or of all the unsubstituted eutomers (1-6, 9, 10, 13) and their eudismic indexes, at any subtype. Thanks to the presence of compounds 11 and 12 in our set of data, we were able to subdivide the data into two groups (by visual inspection) for analysis. The eudismic index of compounds 1-8 (table 1) did not vary significantly with the eutomer pKi value at M₃ receptors, and increased slightly with the pKi value at M₁, M₂ and M₄ receptors. In contrast, the eudismic index of compounds 4, 9-13 and (at M₁ receptors only) 2 varied at least as much as the pKi value of the eutomer, at M₁, M₂ and M₄ receptors. The statistical parameters describing the regression lines (figs. 2 and 3) are summarized in table 3.

4. Discussion

We investigated in this study the binding affinities of the enantiomers of oxyphencyclidine and of tertiary and quarternary compounds structurally related to hexahydro-difenidol and hexbutinol at muscarinic M₁, (NB-OK 1 cells), M₂ (rat heart), M₃ (rat pancreas) and M₄ receptors (rat striatum). Our main goals were to test the hypothesis that eudismic analysis data may be used in receptor classification and to obtain more information about the enantiomer-discriminating properties of muscarinic receptor subtypes.

4.1. Binding profile of the enantiomers and receptor classification

The subtype selectivity of most of the enantiomers studied depended on their absolute configuration. The (R)-enantiomers of compounds 1-13 had a greater affinity for M₁-M₄ receptors than the (S)-isomers (tables 1 and 2). There was no rule governing the relative binding pattern of the (R)- and (S)-enantiomers. For example: (R)-hexahydro-difenidol ((R)-5) and (R)-p-fluoro-hexahydro-difenidol ((R)-7) had low affinities for M₂ receptors (as compared to M₁, M₃ and M₄ receptors), but (S)-5 and (S)-7 were non-selective. In contrast, the two enantiomers of hexbutinol methiodide (10), p-fluoro-hexbutinol (11), p-fluoro-hexbutinol methiodide (12) and oxyphencyclidine (13) had qualitatively the same binding pattern, (R)- and (S)-11 being M₁, M₄ > M₂ selective.

Some of the enantiomer pairs studied are of special interest for receptor classification: for example, (R)-tricyclamol ((R)-2) and (S)-tricyclamol ((S)-4) discriminated with the highest selectivity M₁ from M₂ receptors, but (S)-2 and (S)-4, M₁ from M₃ receptors. (R)-Hexbutinol ((R)-9) discriminated M₁ and M₄ from M₂ receptors, but (S)-9 was M₄ preferring with a low affinity for M₂ and M₁ receptors.

4.2. Stereoselective interaction with muscarinic receptors

Four different groups are bound to the central carbon atom (centre of chirality) of the drugs (1-13) studied in this work: a protonated tertiary or a quarternary ammonium group, a hydroxyl moiety, a phenyl or p-fluorophenyl group, and a cyclohexyl group. Formation of an electrostatic interaction (protonated amino/ammonium group) and/or hydrogen bond must be very important for binding: the cationic ammonium group and the hydroxyl group interact strongly with water when the drug is not bound. These interactions are disrupted when the drug reaches its binding site, and must therefore be replaced by strong interaction with the receptor. On the other hand, the phenyl and cyclohexyl groups do not interact favorably with water: dehydration per se is a favorable process. Binding can be further enhanced by close contact (van der Waals) interactions with the receptor, if the asymmetrically substituted carbon atom has the right absolute configuration (Waelbroeck et al., 1990b, 1991b).

We have previously analyzed the binding properties of the enantiomers of procyclidine (3) and hexahydro-difenidol (5) and of structurally related achiral diphenyl and dicyclohexyl analogues (Waelbroeck et al., 1990b, 1991b). Our results support the hypothesis that procyclidine and hexahydro-difenidol recognize four subsites of the muscarinic receptor, their stereoselectivity reflecting the stronger interaction of (R)-procyclidine ((R)-3) or (R)-hexahydro-difenidol ((R)-5) and weaker interaction of (S)-3 or (S)-5 with the two hydrophobic subsites.

Assuming that all the compounds studied here have the same binding pattern as procyclidine (3) and assuming that the ammonium groups of the two enantiomers form the same type of ionic bond, we expected
the following results: (a) pairs of enantiomers differing only in the structure of their amino (ammonium) groups should have the same eudismic index, at a certain receptor subtype; (b) the phenyl group of the (R)- and (S)-enantiomers recognize, respectively, a phenyl-prefering and a cyclohexyl-prefering subsite (Waelbroeck et al., 1990b, 1991b). p-Fluoro substitution might therefore affect differently the affinity of the two enantiomers and, as a result, change the eudismic index of the compounds. All p-fluoro derivatives, as a group, should however have the same eudismic index at a particular subtype.

Some of our experimental results were in good agreement with these predictions. There was little if any variation of the eudismic index of muscarinic M₁, M₂ and M₄ receptors, for ‘procyclidine-like derivatives’ (compounds 1–8, table 2). However, differences in eudismic indexes for compounds 1–8 were observed at M₃ receptors (tables 1 and 2). This supported the hypothesis that the ionic bond between the anionic subsite of the receptor and the cationic head of the enantiomers of the muscarinic antagonists (1–8) is independent of the drugs’ absolute configuration, at least at M₁, M₂ and M₄ receptors. p-Fluoro substitution affected markedly the eudismic index of hexbutinol (9) and of hexbutinol methiodide (10); the phenyl rings seemed to recognize a different region of the receptor, depending on the absolute configuration of the drug, and this was little affected by N-methylation.

On the other hand: (a) N-methylation of hexahydro-difenidol (5 → 6) and of p-fluoro-hexahydro-difenidol (7 → 8) increased the affinity of the (R)- but not of the (S)-enantiomers for cardiac M₁ receptors; (b) the eudismic indexes of hexbutinol (9), hexbutinol methiodide (10) and oxyphencyclidine (13) were significantly lower than the eudismic indexes of the compounds 1–8 at M₁ and M₂ receptors; (c) p-fluoro substitution of hexahydro-difenidol (5), hexahydro-difenidol methiodide (6), hexbutinol (9) and hexbutinol methiodide (10) did not similarly affect the binding properties of the four (R)- and (S)-enantiomers.

To account for these discrepancies, we would like to suggest that the position and conformation of each compound within the receptor can be adjusted to achieve an optimal overall free energy change. When comparing the enantiomers of procyclidine (3) and tricyclamol (4), or trihexyphenidyl (1) and its methiodide 2, for example, this is not a problem: these compounds are quite similar in size and flexibility and probably recognize the same region in the muscarinic binding site. In contrast, the enantiomers of hexahydro-difenidol (5), hexbutinol (9), their methiodides 6 and 10 and oxyphencyclidine (13) are greater in size and/or more rigid molecules: once the ionic bond between the amino (ammonium) group and the anionic subsite of the receptor is formed the chiral centers of (R)- and (S)-5, 6, 9, 10 and 13 might be unable to reach the same position as (R)- and (S)-procyclidine, respectively. If, as a result, the two hydrophobic cycles of 1–13 come in contact with different regions of a large hydrophobic surface in the muscarinic binding site, we would expect: (a) different eudismic indexes; and (b) different effects of p-fluoro substitution on the binding properties of the ‘procyclidine-like’ drugs (1–8) and ‘hexbutinol-like’ drugs (9–13).

4.3 Application of Pfeiffer’s rule and of its corollary

It is often suggested (Lehmann, 1986) that the eudismic index increases linearly with eutomer potency, not only when comparing a series of related drugs interacting with a single receptor (this is known as ‘Pfeiffer’s rule’) but also when comparing the interaction of a single pair of enantiomers with several different receptors or receptor subtypes. As explained by Barlow (1990), it is plausible that the higher the affinity of the eutomer of a chiral compound, the more it matters how groups are arranged about the centre of chirality. This explains that, as a rule, the eudismic index associated with chiral drugs having a high affinity for the eutomer is larger. Finding a linear correlation between eutomer affinity and eudismic index is, however, far less likely: flexible molecules might have greater affinities and lower eudismic indexes than more rigid molecules, simply because both enantiomers are capable of adapting their conformations to achieve a better fit with the receptors. We expected that finding a linear correlation between eudismic index and affinity for a set of molecules would give valuable information about the drug-binding process. In order to test this hypothesis, we represented our data in figs. 2 and 3 and attempted to find a correlation between eudismic index and eutomer affinity, either for all compounds or for separate sets of the drugs. We found good correlations when grouping compounds 1 → 8 and compounds (2) 4, 9 → 13 in M₁, M₂ and M₄ receptors (table 3).

Most of the compounds in the first group differ in their ammonium (protonated amino) group. The ‘eudismic affinity quotient’ (slope of the regression line) was small: the affinities of the (R)- and of the (S)-enantiomers varied in parallel. This is in good agreement with our hypothesis that the ionic bond is essential for binding of both enantiomers. Two p-fluoro derivatives 7 and 8 also fell in this group. As discussed above, we believe that, in order to allow the hydrogen bindings of the OH group and the ionic interactions of the ammonium moieties, the phenyl group of (R)-hexahydro-difenidol ((R)-5) and (S)-5 recognize different regions of the receptor, and that, by chance, p-fluoro substitution induced the same affinity loss at both subites.
The second group included hexbutinol (9) derivatives and oxyphenecyclimine (13), as well as tricyclamol iodide (4) and (in M1 receptors) trihexyphenidyl methiodide (2). The eudismic index of these drugs increased markedly with eutomor affinity.

We were not surprised to find in the second group hexbutinol (9) and its methiodide (10) and the p-fluorosubstituted derivatives 11 and 12. Indeed, if the phenyl rings of the (R)- and (S)-configured drugs recognize different sites in the muscarinic receptor, p-fluoro substitution may affect differently the binding properties of each enantiomer, and change the eudismic index (table 2). On the other hand, we did not expect to find in the same group oxyphenecyclimine (13), trihexyphenidyl methiodide (2) and tricyclamol iodide (4) which differ from hexbutinol (9) by their ammonium (protonated amino) group.

We would like to suggest that the protonated amino group of the enantiomers of hexbutinol (9) and oxyphenecyclimine (13) forms ionic bonds with an asparagine residue of the receptor. Due to steric hindrance, the positions of the asymmetrically substituted carbon atoms of, for example, the hexbutinol or oxyphenecyclimine enantiomers are, thus, not identical with those of the tricyclamol enantiomers.

In conclusion: using pure enantiomers rather than racemic mixtures can be helpful for receptor classification (the eudismic indexes may serve as an additional criterion for receptor subtype identification, and the binding pattern of the two enantiomers is sometimes very different). Correlations between the eudismic index and high-affinity enantiomer potency, when present, should however be interpreted only with the greatest caution.

Acknowledgements

This work was supported by the Fund for Medical Scientific Research of Belgium (Grant 3.4525.91: J.C. and M.W.), by the Deutsche Forschungsgemeinschaft (R.T.), by the Volkswagen-Stiftung (R.T.) and by the Fonds der Chemischen Industrie (G.L., E.M., and R.T.).

References


Cheng, Y. and W.H. Prusoff, 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes a 50 percent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol. 22, 3099.


Binding characteristics of the muscarinic receptor subtype of the
and antagonists in functional tests. Trends Pharmacol. Sci. 5
(Suppl.), 39.
Richardson, A. and A. Humrich, 1984. A microcomputer program
for the analysis of radioligand binding curves and other dose-
response data, Trends Pharmacol. Sci. 5, 47.
of (S)+1-trihexyphenidyl hydrochloride and (S)-(+)-procycli-
dine hydrochloride, two anticholinergics, using (S)+ -3-cyclohex-
yl-3-hydroxy-3-phenyltopanonic acid as chiral synthons, Acta
Schjelderup, L., M.R. Kozlowski, A. Weissman and A.J. Aasen,
1988. Antimuscarinic effects of (R)- and (S)-oxyphenemeline
hydrochloride, Pharm. Recs. 5, 236.
Strohmann, C., S. Bauerecker, H.K. Cammeanga, P.G. Jones, E.
muscarinic antagonist 1-cyclohexyl-1-(4-fluorophenyl)-4-
piperidinio-1-butanol (p-fluoro-hexahydro-difenidol): synthesis,
absolute configuration and enantiomeric purity, Liebigs Ann.
Chem. 523.
Tacke, R., H. Lincic, D. Schomburg, L. Ernst, U. Moser, E. Mutschcher
and G. Lambrecht, 1986. On the absolute configuration of the
enantiomers of the antimuscarinic agent pencyclidine and triey-
chol iodide: X-ray structural analysis of (R)-1-[3-cyclohexyl-3-
hydroxy-3-phenylpropyl]-1-methylpyrrolidinium iodide. Liebigs
Tacke, R., C. Strohmann, S. Sarge, H.K. Cammena, D. Schomburg,
E. Mutschler and G. Lambrecht, 1989. Preparation and properties
of the enantiomers of the selective antimuscarinic agent
1-cyclohexyl-1-phenyl-4-piperidino-1-butanol (hexahydro-difen-
idol), Liebigs Ann. Chem. 137.
Binding of selective antagonists to four muscarinic receptors (M1
Waehrboeck, M., J. Camus, M. Tastenoy, G. Lambrecht, E. Mutschler,
R. Tacke and J. Christophe, 1990b. Stereoselectivity of procycli-
dine binding to muscarinic receptor subtypes M1, M2 and M4,
Waehrboeck, M., J. Camus, M. Tastenoy, G. Lambrecht, E. Mutschler,
C. Strohmann, R. Tacke and J. Christophe, 1991a. Binding affini-
ties of hexahydro-difenidol and hexahydr-o-sila-difenidol ana-
lagles at four muscarinic receptor subtypes: constitutional and
95.
Wachboeck, M., J. Camus, M. Tastenoy, E. Mutschler, C. Strohmann,
R. Tacke, G. Lambrecht and J. Christophe, 1991b, Stereoselectiv-
ity of (R)- and (S)-hexahydro-difenidol binding to neuroblastoma
M1, cardiac M2, pancreatic M3 and striatum M4 muscarinic
receptors. Chirality 3, 118.